Clinicopathological discordance and survival outcomes in 154 breast cancer patients with pulmonary metastasis in a real-world setting Authors: Ying Yan, Yifei Chen, Lijun Di, Xu Liang, Bin Shao, Hanfang Jiang, Guohong Song, Huiping Li Published: 2026 ABSTRACT AbstractPurposeThis study aimed to investigate the clinicopathological significance of pulmonary metastasis in breast cancer patients and to evaluate the prognostic outcomes of lung metastasis subtypes.MethodsA retrospective analysis was conducted on breast cancer patients who underwent lung nodule biopsy at Peking University Cancer Hospital between 2010 and 2024. We identified 180 biopsied patients. Analyses of receptor discordance and survival were performed in the 154 pulmonary metastasis cases and primary lung cancers were described only for differential diagnosis.ResultsAmong 2,857 breast cancer patients with lung nodules, 180 (6.3%) underwent pathological confirmation, including 154 (85.6%) with breast cancer lung metastases and 26 (14.4%) with primary lung cancers. In 128 patients with complete receptor profiles, the overall discordance rate between primary and metastatic lesions was 18.0% (95% CI, 11.2–24.7). The discordance rates for ER, PR, and HER2 were 10.9%, 26.6%, and 10.9%, respectively. Based on metastatic receptor status, 73 (47.4%) patients were classified as HR+/HER2-, 44 (28.6%) as HER2+, and 37 (24.0%) as triple-negative, with 3-year overall survival rates of 95.9%, 94.1%, and 65.3%, respectively (P < 0.001).ConclusionLung biopsy is indispensable for reassessing receptor status to guide systemic therapy and for differentiating metastatic lesions from primary lung cancers. Receptor heterogeneity between primary and metastatic sites was observed, and survival outcomes varied across lung metastasis subtypes.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s12672-026-05451-w.Keywords: Breast cancer, Lung metastasis, Receptor heterogeneity, Prognosis Introduction Breast cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related death in women worldwide, followed by lung cancer. In 2022, approximately 2.3 million new breast cancer cases and 0.9 million new lung cancer cases were reported, accounting for 23.8% and 9.4% of all newly diagnosed cancers among women, respectively [1]. Pulmonary nodules are commonly detected on computed tomography (CT) scans, with a prevalence of 30–40% in screening populations [2]. Although most pulmonary nodules are benign in the general population, their presence in breast cancer patients, either during preoperative staging or postoperative surveillance, raises significant concern for malignancy. For breast cancer patients, pulmonary nodules with malignant radiologic features are often presumed to represent lung metastases. However, considering patients with breast cancer have a higher likelihood of developing primary lung cancer compared with the general population [3], the possibility of primary lung cancer must not be overlooked. Pathological confirmation through biopsy is therefore essential, not only to provide biomarker information that informs systemic treatment decisions for advanced breast cancer, but also to differentiate between metastatic and primary malignancies. The classification of metastatic breast cancer by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) forms the foundation of systemic treatment selection. Current guidelines, including those from the National Comprehensive Cancer Network (NCCN) [4] and the European School of Oncology International Consensus Guidelines for Advanced Breast Cancer [5], strongly recommend biopsy of metastatic lesions at initial recurrence to confirm the diagnosis and reassess receptor status. Nevertheless, compared with liver or lymph node biopsies, lung biopsy is technically more challenging and carries higher complication risks, contributing to its relatively lower utilization in routine practice [6]. While several studies have addressed the diagnostic role of lung biopsy in distinguishing metastases from primary lung cancers [7–9], robust evidence regarding receptor conversion in lung metastases and its prognostic implications remains limited due to small sample sizes. To address the gaps, we conducted a retrospective study of 180 breast cancer patients who underwent biopsy or surgical resection of lung nodules. The primary objectives were to assess receptor heterogeneity between primary breast tumors and lung metastases and to evaluate survival outcomes across different metastatic subtypes. Patients and methods Study population Among 2,857 breast cancer patients with clinically suspected lung metastases or primary lung cancers, 180 patients who underwent lung biopsy or surgery and were treated at Peking University Cancer Hospital between February 2010 and December 2024 were retrospectively analyzed. Eligible patients were required to meet the following criteria: (1) histologically confirmed breast cancer with lung metastases or primary lung cancers; (2) availability of ER, PR, and HER2 status for lung metastatic lesions; and (3) complete clinicopathological and follow-up data. Male patients and those lacking essential clinical or follow-up data were excluded. Data collection Clinical data were extracted from medical records, including age of breast cancer diagnosis and lung biopsy diagnosis, initial stage (American Joint Committee on Cancer (AJCC) 7th edition), histological type, tumor grade, ER/PR/HER2 status at baseline, surgical procedures, metastatic sites, time interval between the diagnosis of primary breast cancer and the onset of distant metastasis and/or lung nodules, overall survival (OS) after lung biopsy, and the follow-up information. Pathology assessment ER, PR, and HER2 status of lung metastatic lesions were assessed in accordance with the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines [10, 11]. The results were further categorized into HR+/HER2-, HER2+, or triple-negative (TNBC) following the widely adopted classification principles used in clinical practice. The staining of ER (Estrogen Receptor) and PR (Progesterone Receptor) is identified by the presence of yellow or brown granules within the nucleus. A sample is considered positive for ER or PR if ≥ 1% of tumor cell nuclei exhibit immunoreactivity [10]. HER2-overexpressing tumors based on immunohistochemistry (IHC) 3 + or IHC 2 + with confirmation of HER2 gene amplification through in situ hybridization (ISH) positivity are defined as HER2-positive, while tumors with IHC 0, 1+, or 2 + with ISH negativity are defined as HER2-negative [11]. For differential diagnosis of primary lung cancer from breast cancer lung metastases, morphology and immunohistochemical markers including ER, GATA3, mammaglobin, and thyroid transcription factor-1 (TTF-1) were used [12, 13]. Statistical analysis Descriptive statistics were utilized to summarize baseline data for the study cohort. The distribution of tissue-acquisition procedures according to pulmonary lesion pattern was compared using Pearson’s chi-square test. Concordance rates for ER, PR, and HER2 between primary lesions and lung metastatic lesions were evaluated using the Kappa test. A Kappa value of ≥ 0.6 indicated strong concordance, while a value ≤ 0.4 denoted weak concordance [14]. To explore factors associated with receptor discordance between primary breast tumors and pulmonary lesions, an exploratory multivariable binary logistic regression analysis was performed using receptor discordance (concordant vs. discordant) as the dependent variable. Primary subtype was entered as a categorical variable, with HR+/HER2-disease used as the reference category. Age at lung biopsy and the interval from breast cancer to pulmonary metastasis were included as covariates. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported. Overall survival (OS) was calculated using the Kaplan-Meier method, with differences between survival curves assessed via the log-rank test. OS was defined as the duration from the date of pulmonary metastatic confirmation to the date of death from any cause or the last follow-up. The latest follow-up was completed in August 2025. To further evaluate factors associated with OS, univariable and multivariable Cox proportional hazards regression analyses were performed. The variables assessed included pathological subtype, first recurrence site, age at lung biopsy, the interval from breast cancer to pulmonary metastasis, and the number of pulmonary metastatic lesions. Sensitivity Cox analyses were additionally performed by including tissue-acquisition procedure in the model. Pathological subtype was entered as a categorical variable, with HR-positive/HER2-negative disease as the reference category. Hazard ratios (HRs) and 95% CIs were reported. Given the limited number of OS events, the number of covariates included in the multivariable model was restricted to reduce overfitting. Results were deemed statistically significant if the P-value was < 0.05. Data analysis was performed using SPSS version 21 (SPSS Inc., Chicago, IL) and GraphPad Prism 10 (GraphPad Software Inc.), while Sankey diagram was generated using Sangerbox 3.0 (http://vip.sangerbox.com/). A two-sided P-value < 0.05 was considered statistically significant. Ethics This study was approved by the Independent Ethics Committee of Peking University Cancer Hospital (Ethics Approval License No. 2020KT75). Given the retrospective nature, the requirement for informed consent was waived. All procedures were performed in accordance with the Declaration of Helsinki. Results Patient characteristics Among 2,857 breast cancer patients with pulmonary lesions detected by chest CT or PET/CT, 180 patients (6.3%) underwent pathological confirmation by lung biopsy or surgery. Of these, 154 (85.6%) were diagnosed with breast cancer lung metastases and 26 (14.4%) with secondary primary lung malignancies. The median age at primary breast cancer diagnosis was 49 years (range, 24–70), and most patients presented with stage 0-III disease (95.6%) and underwent radical surgery (94.4%). Invasive ductal carcinoma accounted for the vast majority of primary tumors (91.1%). The median disease-free survival among patients who received radical surgery was 46.0 months (95% CI, 34.9–57.1). The median age at lung biopsy was 55 years (range, 24–77). More than half of lung biopsies/surgeries were performed during 2020–2024 (53.2%), and biopsies were obtained at the time of first detection of pulmonary nodules in 90.9% of cases. CT-guided biopsy was the most common diagnostic procedure (51.9%), followed by thoracic surgery (38.3%) and transbronchial biopsy (9.8%) (Tables 1 and 2). Table 1Basic characteristics of the patients for primary breast cancerCharacteristicn(%)All180 (100)Age(years)-primary breast cancer diagnosisMedian(min-max)49 (24–70)Year of initial breast cancer diagnosis <20007 (3.9) 2000–200932 (17.8) 2010–201998 (54.4) 2020–202443 (23.9)Histology of primary tumor IDC164 (91.1) ILC2 (1.1) Other12 (6.7) Unknown2 (1.1)Stage at initial breast cancer diagnosis Stage 0-III172 (95.6) Stage IV8 (4.4)Radical surgery for primary breast cancer Yes170 (94.4) No10 (5.6)DFS for radical surgery patients (months)Median (95%CI)46.0 (34.9–57.1) ER status of primary tumor ER-positive91 (50.5) ER-negative68 (37.8) Unknown21 (11.7)PR status of primary tumor PR-positive86 (47.8) PR-negative73 (40.6) Unknown21 (11.7)HER2 status of primary tumor 0 and 1+87 (48.3) 2 + and FISH(-)19 (10.6) 2 + and FISH(+)10 (5.6) 2 + but without FISH3 (1.7) 3+37 (20.6) Unknown24 (13.3)IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; DFS: disease free survival; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor-2; FISH: fluorescence in situ hybridization Basic characteristics of the patients for primary breast cancer Age(years)-primary breast cancer diagnosis Median(min-max) DFS for radical surgery patients (months) Median (95%CI) IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; DFS: disease free survival; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor-2; FISH: fluorescence in situ hybridization Table 2Lung nodules biopsy characteristics in patients with lung metastasisCharacteristicBreast cancer lung metastasisN(%)All154 (100)Age(years)-lung biopsyMedian(min-max)55 (24–77)Year of lung biopsy 2010–201413 (8.5) 2015–201959 (38.3) 2020–202482 (53.2)Involved/metastatic sites lung only124 (80.5) Others (bone, liver, etc.)30 (19.5)Biopsy at first lung nodules detected Yes140 (90.9) No14 (9.1)Biopsy pattern CT-guided biopsy80 (51.9) Thoracic surgery59 (38.3) Transbronchial biopsy15 (9.8)Number of lung nodules 180 (51.9) 24 (2.6) >=370 (45.5)Interval from the diagnosis for primary breast cancer to lung biopsyMedian (95%CI) < 6 months11 (7.1) 6 months to 3 years52 (33.8) 3 years to 5 years29 (18.8) >5 years62 (40.3)ER status of lung metastasis ER-positive85 (55.2) ER-negative69 (44.8)PR status of lung metastasis PR-positive65 (42.2) PR-negative89 (57.8)HER2 status of lung metastasis 0 and 1+87 (56.5) 2 + and FISH(-)23 (14.9) 2 + and FISH(+)9 (5.8) 3+35 (22.7)Subtype of lung metastasis HR+/HER2-73 (47.4) HER2-positive44 (28.6) TNBC37 (24.0)CT: computed tomography; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor-2; FISH: fluorescence in situ hybridization Lung nodules biopsy characteristics in patients with lung metastasis Age(years)-lung biopsy Median(min-max) Interval from the diagnosis for primary breast cancer to lung biopsy Median (95%CI) CT: computed tomography; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor-2; FISH: fluorescence in situ hybridization Patterns of pulmonary involvement and timing of diagnosis Of the 154 patients with lung metastases, 124 (80.5%) presented with lung-only disease, while 30 (19.5%) had additional metastatic sites. At the time of biopsy, approximately half of metastasis cases presented with a solitary nodule (51.9%), whereas multiple nodules (≥ 3) were also common (45.5%). Among patients with solitary pulmonary lesions, 41 of 80 underwent thoracic surgery (51.2%), compared with 18 of 74 patients with ≥ 2 pulmonary lesions (24.3%). The distribution of tissue-acquisition procedures differed significantly between solitary and ≥ 2 pulmonary lesions (P < 0.001) (Supplementary Table S1). The time interval from primary breast cancer diagnosis to lung biopsy showed marked heterogeneity. In the lung metastasis group (n = 154), 40.3% of cases were diagnosed more than 5 years after initial breast cancer diagnosis, whereas only 7.1% occurred within 6 months. In contrast, among 26 patients ultimately diagnosed with secondary primary lung cancers, 38.5% underwent lung biopsy within 6 months of breast cancer diagnosis, highlighting the importance of pathological confirmation when pulmonary lesions emerge early in the disease course. Receptor discordance between primary tumor and lung metastases Among 128 patients with complete receptor status information for both primary breast tumors and lung metastases, the overall discordance rate was 18.0% (95% CI, 11.2–24.7), with a Kappa coefficient of 0.72 (Table 3). The discordance rates for ER, PR and HER2 were 10.9% (95%CI, 5.5–16.4), 26.6% (95%CI, 18.8–34.3), and 10.9% (95%CI, 5.5–16.4), respectively. Concordance was highest for ER (κ = 0.78), moderate for HER2 (κ = 0.73), and lowest for PR (κ = 0.47) (Table 3). Table 3ER, PR and HER2 discordance rate between primary tumor and lung metastasis biopsyPrimary tumorLung biopsyKappa valuePositive, n(%)Negative, n(%)Total, n(%)ER Positive60 (84.5)11 (15.5)71 (100)0.78 Negative3 (5.3)54 (94.7)57 (100) Total6365128 DR(95%CI)10.9% (5.5–16.4)PR Positive40 (60.6)26 (39.4)66 (100)0.47 Negative8 (12.9)54 (87.1)62 (100) Total4880128 DR(95%CI)26.6% (18.8–34.3)HER2 Positive (3 + or amplified)30 (83.3)6 (16.7)36 (100)0.734 Negative (< 3 + or not amplified )8 (8.7)84 (91.3)92 (100) Total3890128 DR(95%CI)10.9 % (5.5–16.4)HR: hormone receptor; HER2: human epidermal growth factor receptor-2; DR: discordance rate ER, PR and HER2 discordance rate between primary tumor and lung metastasis biopsy HR: hormone receptor; HER2: human epidermal growth factor receptor-2; DR: discordance rate Subtype shifts were observed: among HR+/HER2- primary tumors (n = 61), 5(8.2%) converted to HER2 + and 5(8.2%) to triple-negative disease. Of HER2 + primaries (n = 36), 6 (16.7%) converted to other subtypes, including 5 (13.9%) to triple-negative and 1 (2.8%) to HR+/HER2-. Among triple-negative primaries (n = 31), 7 (22.6%) converted to HR+/HER2- (n = 4, 12.9%) or HER2 + disease (n = 3, 9.7%) (Table 4; Fig. 1). No significant association was observed between primary subtype and receptor discordance overall (P = 0.75) (Table 5). Table 4Subtype differences between primary breast tumor and lung metastasis biopsyPrimary tumorLung biopsyKappa valueHR+/HER2-n(%)HER2-positiven(%)TNBCn(%)HR+/HER2-n = 6151 (83.6)5 (8.2)5 (8.2)0.72HER2-positiven = 361 (2.8)30 (83.3)5 (13.9)TNBCn = 314 (12.9)3 (9.7)24 (77.4)Totaln = 12856 (43.8)38 (29.7)34 (26.6)DR(95%CI)18.0% (11.2–24.7)HR: hormone receptor; HER2: human epidermal growth factor receptor-2; DR: discordance rate Subtype differences between primary breast tumor and lung metastasis biopsy HR+/HER2- n = 61 HER2-positive n = 36 TNBC n = 31 Total n = 128 HR: hormone receptor; HER2: human epidermal growth factor receptor-2; DR: discordance rate Subtypes transformation of primary breast cancer and lung metastasis in 128 cases. HR: hormone receptor; HER2: human epidermal growth factor receptor-2; TNBC: triple negative breast cancer Table 5Exploratory multivariable logistic regression analysis for receptor discordance between primary breast tumors and pulmonary lesionsVariableOR95% CIP valuePrimary subtype0.75HR+/HER2-ReferenceHER2 + vs. HR+/HER2-1.0180.329–3.1470.98TNBC vs. HR+/HER2-1.5070.482–4.7140.48Age at lung biopsy, per year1.0050.962–1.0510.81Pulmonary metastasis interval, per month1.0000.990–1.0100.97Pulmonary metastasis interval was defined as interval from initial breast cancer diagnosis to pulmonary metastasis. The multivariable model was exploratory and based on 128 complete casesOR: odds ratio; CI: confidence interval; HER2: human epidermal growth factor receptor-2; HR+/HER2-: Hormone receptor-positive/HER2 negative; TNBC: triple-negative breast cancer Exploratory multivariable logistic regression analysis for receptor discordance between primary breast tumors and pulmonary lesions Pulmonary metastasis interval was defined as interval from initial breast cancer diagnosis to pulmonary metastasis. The multivariable model was exploratory and based on 128 complete cases OR: odds ratio; CI: confidence interval; HER2: human epidermal growth factor receptor-2; HR+/HER2-: Hormone receptor-positive/HER2 negative; TNBC: triple-negative breast cancer Survival outcomes by subtype Based on the receptor status of lung metastases, 73 patients (47.4%) were classified as HR+/HER2-, 44 (28.6%) as HER2+, and 37 (24.0%) as TNBC. Significant differences in 3-year OS were observed across three groups: 95.9% for HR+/HER2-, 94.1% for HER2+, and 65.3% for triple-negative disease (P < 0.001) (Fig. 2). We further evaluated the prognostic impact of tissue-acquisition procedure. The 3-year OS rates were 90.9%, 80.2%, and 85.1% in the thoracic surgery, transbronchial biopsy, and CT-guided biopsy groups, respectively, with no significant difference among the three groups (P = 0.97). Overall survival of the patients among different subtypes. HR: hormone receptor; HER2: human epidermal growth factor receptor-2; TNBC: triple negative breast cancer In the multivariable Cox model, pathological subtype remained significantly associated with OS overall (P < 0.001). Compared with HR+/HER2- disease, TNBC was independently associated with significantly worse OS (HR 11.897, 95% CI 3.298–42.915, P < 0.001), whereas HER2-positive disease was not significantly different from HR+/HER2- disease (HR 0.844, 95% CI 0.188–3.793, P = 0.83). In addition, multiple pulmonary metastatic lesions were independently associated with worse OS compared with solitary pulmonary metastatic lesions (HR 2.897, 95% CI 1.069–7.853, P = 0.04). Age at lung biopsy showed a non-significant trend toward worse OS (HR 1.047, 95% CI 0.994–1.103, P = 0.09), while pulmonary metastasis interval and first recurrence site were not significantly associated with OS (Table 6). Sensitivity Cox analyses also showed that tissue-acquisition procedure was not significantly associated with OS in either univariable or multivariable models (Supplementary Table S2). Table 6Univariable and multivariable Cox proportional hazards regression analyses for overall survivalVariableUnivariable HR (95% CI)P valueMultivariable HR (95% CI)P valuePathological subtype< 0.001< 0.001HR+/HER2-ReferenceReferenceHER2 + vs. HR+ /HER2-0.801 (0.197–3.263)0.760.844 (0.188–3.793)0.83TNBC vs. HR+/HER2-6.747 (2.342–19.435)< 0.00111.897 (3.298–42.915)< 0.001Age at lung biopsy, per year1.030 (0.980–1.083)0.251.047 (0.994–1.103)0.09Pulmonary metastasis interval, per month0.996 (0.988–1.003)0.280.999 (0.992–1.007)0.85First recurrence (lung only vs. lung plus other metastatic sites)0.992 (0.289–3.410)0.991.190 (0.304–4.655)0.80Number of pulmonary metastatic lesions (multiple vs. solitary)1.674 (0.673–4.164)0.272.897 (1.069–7.853)0.04Pulmonary metastasis interval was defined as interval from initial breast cancer diagnosis to pulmonary metastasisCI: confidence interval; HR: hazard ratio; HER2: human epidermal growth factor receptor-2; HR+/HER2-:Hormone receptor-positive/HER2 negative; TNBC: triple-negative breast cancer Univariable and multivariable Cox proportional hazards regression analyses for overall survival Pulmonary metastasis interval was defined as interval from initial breast cancer diagnosis to pulmonary metastasis CI: confidence interval; HR: hazard ratio; HER2: human epidermal growth factor receptor-2; HR+/HER2-:Hormone receptor-positive/HER2 negative; TNBC: triple-negative breast cancer Discussion In breast cancer patients, newly detected pulmonary nodules during surveillance are most often presumed to represent metastatic disease [7]. However, only 6.3% of patients with pulmonary lesions in this study underwent lung biopsy, a proportion considerably lower than that for liver biopsy at our institution (542/2025, 26.8%) [15]. Among patients who underwent biopsy for pulmonary metastases, 80.5% had lung-only involvement. For these patients, lung biopsy is particularly important. In cases with multiple metastatic sites, clinicians may diagnose breast cancer metastasis based on the overall clinical context or preferentially biopsy another more accessible metastatic site. This discrepancy is largely attributable to the greater technical complexity and higher risk of complications associated with percutaneous CT-guided transthoracic or transbronchial biopsy compared with ultrasound-guided procedures for liver or soft-tissue lesions. Despite being an effective and minimally invasive diagnostic technique, percutaneous CT-guided transthoracic biopsy is associated with notable risks, most commonly pneumothorax (reported in up to 62% of cases) and pulmonary hemorrhage [6]. In our study, CT-guided biopsy was the most used method (51.9%), followed by thoracic surgery (38.3%). Although solitary nodules were more frequent in patients with primary lung cancer than in those with metastatic lesions (65.4% vs. 51.9%), this radiologic pattern alone is insufficient to exclude metastasis. Likewise, the interval between breast cancer surgery and the appearance of pulmonary nodules is not a reliable indicator for distinguishing primary lung cancer from metastatic disease. Of note, 40.3% of patients with lung metastases in our study were diagnosed more than five years after definitive breast surgery, underscoring the long-term risk of late recurrence in breast cancer survivors. Thoracic surgery may have both diagnostic and potential therapeutic implications [9, 28], particularly for solitary pulmonary lesions. In clinical practice, however, solitary pulmonary nodules in breast cancer patients may also undergo CT-guided or transbronchial biopsy before surgery to distinguish pulmonary metastasis from primary lung cancer and guide multidisciplinary treatment decisions. In our cohort, thoracic surgery was more frequently performed in patients with solitary pulmonary lesions, suggesting real-world selection of patients with lower disease burden and potentially resectable disease. This pattern may reflect the established therapeutic role of surgery for primary lung cancer and its potential role as metastasis-directed local treatment in selected patients with oligometastatic breast cancer. However, tissue-acquisition procedure was not significantly associated with OS in Kaplan-Meier analysis or sensitivity Cox analyses. These findings do not support an independent prognostic impact of tissue-acquisition procedure, although they should be interpreted cautiously given the limited sample size within each subgroup and potential confounding by lesion burden, tumor subtype, surgical candidacy, and pathological diagnosis. A total of 154 patients were diagnosed with breast cancer lung metastases in our cohort. Among them, 128 patients had complete receptor status data for both primary breast tumors and corresponding lung metastatic lesions, allowing assessment of receptor conversion. Discordance rates were 10.9% (95% CI, 5.5–16.4) for ER, 26.6% (95% CI, 18.8–34.3) for PR, and 10.9% (95% CI, 5.5–16.4) for HER2 expression, resulting in an overall discordance rate of 18.0% (95% CI, 11.2–24.7) across all three subtypes (HR+/HER2-, HER2+, and triple-negative). This rate was slightly lower than the 23.6% discordance previously reported in breast cancer liver metastases at our center [15]. Although the lung and liver represent the two most common visceral metastatic sites in breast cancer, molecular and microenvironmental differences may underlie the organ-specific variations in receptor conversion, as suggested by several studies on metastatic organotropism [16, 17]. The ER discordance rate observed in our cohort (10.9%) was slightly lower than that reported in previous studies, as large-scale investigations have documented receptor discordance between primary and metastatic lesions in 15–40% of cases for ER/PR and 7–26% for HER2 [18–20]. We additionally performed an exploratory multivariable logistic regression analysis to investigate factors associated with receptor discordance between primary breast tumors and pulmonary lesions. No significant association was identified for primary subtype, age at lung biopsy, or the interval from breast cancer to pulmonary metastasis. These findings suggest that, within the limits of the present dataset, receptor discordance could not be reliably predicted by the clinicopathological variables assessed. Given the limited number of discordance events (n = 23), these analyses should be interpreted as exploratory. While most primary breast cancers co-express ER and PR, loss of one or both receptors during disease progression has been reported. In our study, PR loss occurred in 39.4% of patients (26/66), which was notably higher than ER loss (15.5%, 11/71). A nationwide multicenter epidemiological study from China similarly demonstrated that PR conversion is more common than ER conversion and is associated with poorer overall survival [21]. The biological mechanisms responsible for PR loss remain incompletely understood but may involve endocrine resistance during adjuvant therapy and a transition toward a more aggressive metastatic phenotype [22]. From a treatment perspective, reassessment is most impactful when the metastatic profile changes eligibility for targeted agents (e.g., acquisition or loss of HER2 positivity) or when unexpected loss of hormone receptor expression may prompt reconsideration of endocrine-based strategies. Even when changes are confined to PR, the finding may signal evolving endocrine sensitivity and warrants careful integration with clinical course and prior therapy exposure rather than automatic escalation. Based on the receptor status of lung metastases, 73 patients (47.4%) were classified as HR+/HER2-, 44 (28.6%) as HER2+, and 37 (24.0%) as triple-negative. Significant differences in 3-year OS were observed among these subtypes: 95.9% for HR+/HER2−, 94.1% for HER2+, and 65.3% for triple-negative disease (P < 0.001). In the Cox regression analyses, pathological subtype remained strongly associated with OS in this cohort. After adjustment for selected clinicopathological variables, TNBC was associated with significantly worse survival than HR+/HER2- disease, whereas HER2 + disease did not differ significantly from HR+/HER2- disease. These survival differences likely reflect the availability and efficacy of targeted systemic therapies. The incorporation of CDK4/6 inhibitors into endocrine-based regimens has markedly improved outcomes for HR+/HER2- patients [23, 24], while the development of HER2-targeted agents such as pertuzumab, trastuzumab, and trastuzumab deruxtecan has led to substantial survival gains in HER2 + disease [25, 26]. The possibility of secondary primary lung cancer should not be underestimated, as it accounts for nearly 5% of second primary malignancies among breast cancer survivors [27]. In our cohort, 26 patients (14.4%) were diagnosed with primary lung malignancies. Population-based studies have demonstrated that breast cancer survivors, particularly younger women and those without comorbidities, are at an elevated risk of developing secondary lung cancers compared with the general population [28, 29]. This association may be partly explained by the relatively high incidence of both malignancies in women and by potential shared genetic or environmental susceptibilities. These findings reinforce the clinical importance of histologic verification of pulmonary nodules in breast cancer patients. Lung biopsy not only enables precise differentiation between metastasis and secondary primary malignancy but also provides up-to-date receptor information essential for optimizing systemic therapy. To our knowledge, this study is one of the largest analyses to date of receptor conversion in pulmonary metastases from breast cancer. However, several limitations should be acknowledged. First, due to the real-world retrospective design, selection bias could not be fully avoided. A relatively high proportion of patients in this cohort had lung-only metastasis, which likely reflects a greater tendency in routine clinical practice to pursue pathological evaluation in patients with isolated pulmonary lesions. Consistent with our Cox regression analysis, multiple pulmonary metastatic lesions were independently associated with worse OS than solitary pulmonary metastatic lesions. Therefore, the predominance of lung-only or limited metastatic disease in this cohort may have contributed to the relatively favorable survival observed in this selected population. In addition, patients who were able to undergo an invasive lung biopsy procedure may have had better physical performance status and financial resources, and thoracic surgery was more often selected for those with solitary and potentially resectable pulmonary lesions. These factors could further contribute to selection bias and limit the generalizability of our findings. Second, overall survival was calculated from the date of lung biopsy rather than from the diagnosis of metastatic disease. Therefore, immortal time bias cannot be excluded, because patients had to survive long enough to undergo biopsy in order to be included in the cohort, which may have contributed to a longer observed OS in this selected population. Third, this study spanned a relatively long inclusion period. Given the rapid evolution of treatment strategies for advanced breast cancer in recent years, unavoidable heterogeneity existed in the therapeutic regimens received by patients enrolled at different time points. Finally, the sample size within each subtype was relatively small, limiting our ability to explore additional prognostic factors. Prospective multicenter studies with larger cohorts are needed to validate these findings and further clarify the prognostic and therapeutic value of lung biopsy in breast cancer patients with pulmonary nodules. In conclusion, accurate classification of newly detected pulmonary nodules after curative breast cancer surgery remains challenging despite advances in imaging. Given the substantial prognostic differences across metastatic subtypes, particularly the poor outcomes associated with metastatic TNBC, multidisciplinary evaluation and a risk-informed biopsy strategy may optimize both diagnostic accuracy and treatment selection. Histopathological confirmation through lung biopsy remains indispensable not only for differentiating metastasis from secondary primary lung malignancy but also for updating receptor status to subsequent treatment strategies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Author contributions Y. Y, YF. C, GH.S and HP. L contributed to the conceptualization, formal analysis, and writing-original draft, and were the major contributors in writing the manuscript. Y.Y, YF.C, LJ. D, HF. J, X. L and B. S collected, analyzed and interpreted the data. Y.Y and YF.C contributed to investigation, methodology, project administration, and review and editing. All authors read and approved the final manuscript. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Independent Ethics Committee of Peking University Cancer Hospital (Ethics Approval No. 2020KT75). All procedures were performed in accordance with the Declaration of Helsinki. Given the retrospective nature of the study, the requirement for informed consent was waived by the Independent Ethics Committee of Peking University Cancer Hospital. Consent for publication Not applicable. This study does not contain any identifiable individual participant data. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Ying Yan and Yifei Chen have contributed equally to this work. Contributor Information Guohong Song, Email: songguohong918@hotmail.com. Huiping Li, Email: huipingli2012@hotmail.com. References Associated Data Data Availability Statement The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.